^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer

    Published date:
    05/23/2016
    Excerpt:
    Targeted Therapy: Exemestane and everolimus may be offered to postmenopausal women with HR-positive MBC who experienced during prior treatment with nonsteroidal AIs with or without one line of prior chemotherapy, either before or after treatment with fulvestrant, because PFS but not OS was improved compared with exemestane alone.
    Secondary therapy:
    exemestane
    DOI:
    10.1200/JCO.2016.67.1487
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Negative Breast Cancer)
    New
    Excerpt:
    Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

    Excerpt:
    ......
    Trial ID:
    UNIRAD
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Dose EScalation Induction of EvERolimus

    Excerpt:
    ...symptomatic visceral metastasis) -Histological confirmed hormone receptor-positive (HR+), HER2- negative carcinoma of the breast....
    Trial ID:
    Desiree
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

    Excerpt:
    ...- Patients must have a histologically confirmed diagnosis of hormone receptor positive, HER2 negative invasive breast carcinoma....
    Trial ID:
    NCT02236572
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

    Excerpt:
    ...- Metastatic breast cancer HR+ (Hormone Receptor positive), HER2/neu negative (Human Epidermal Growth Factor Receptor-2)...
    Trial ID:
    RAPANK
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

    Excerpt:
    ...Histological confirmation of hormone-receptor positive (defined as at least 10% of estrogen receptor (ER) and/or progesterone receptor (PgR) positivity) and human epidermal growth factor receptor 2 (HER2) negative (score 0-1+ in immunohistochemistry or FISH negativity) breast cancer 3....
    Trial ID:
    MAIN-A
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Everolimus TDM to Predict Long Term Toxicity

    Excerpt:
    ...- Patients currently treated with everolimus for any type of cancer, such as the EMA registered indications i.e. advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer, metastatic renal cell carcinoma (mRCC) or neuroendocrine tumour (NET) of pancreatic, gastrointestinal or lung origin....
    Trial ID:
    Foresight
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

    Excerpt:
    ...- Postmenopausal advanced hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer after failure of treatment with letrozole or anastrozole...
    Trial ID:
    NCT02273752
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

    Excerpt:
    ...- Postmenopausal hormone receptor positive patients should have received an aromatase inhibitor in any given previous breast cancer therapy....
    Trial ID:
    RADAR
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A randomized discontinuation phase II study to determine the efficacy of RAD001 in breast cancer patients with bone metastases

    Excerpt:
    ...Postmenopausal hormone receptor positive patients should have received an aromatase inhibitor in any given previous breast cancer therapy. ...
    Trial ID:
    2005-005835-87